Heart failure therapy at a crossroad: are there limits to the neurohormonal model?

Weber, 2002, CHF, Congest Heart Fail, 8, 37, 10.1111/j.1527-5299.2002.00720.x Francis, 2001, Pathophysiology of chronic heart failure, Am J Med, 110, 37S, 10.1016/S0002-9343(98)00385-4 Willenbrock, 2000, Neurohumoral blockade in CHF management, J Renin Angiotensin Aldosterone Syst, 1, 24, 10.3317/jraas.2000.030 Packer, 1999, Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure, Circulation, 100, 2312, 10.1161/01.CIR.100.23.2312 Nanas, 2000, Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril, J Am Coll Cardiol, 36, 2090, 10.1016/S0735-1097(00)01025-1 Tang, 2002, Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure, J Am Coll Cardiol, 39, 70, 10.1016/S0735-1097(01)01714-4 Cohn, 2001, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med, 345, 1667, 10.1056/NEJMoa010713 Nawarskas, 2000, Omapatrilat, Heart Dis, 2, 266 McDowell, 1997, The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides, Br J Clin Pharmacol, 43, 329, 10.1046/j.1365-2125.1997.00545.x Packer, 2002, Comparison of omapatrilat and enalapril in patients with chronic heart failure, Circulation, 106, 920, 10.1161/01.CIR.0000029801.86489.50 Louis, 2001, Clinical trials update, Eur J Heart Fail, 3, 381, 10.1016/S1388-9842(01)00149-0 Williams, 2002, Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session, J Am Coll Cardiol, 40, 1, 10.1016/S0735-1097(02)01982-4 Swedberg, 2002, Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure, Circulation, 105, 1797, 10.1161/01.CIR.0000014212.04920.62 Bristow, 2001, Baseline and three-month change in systemic venous norepinephrine as predictors of clinical outcomes in the BEST trial, J Am Coll Cardiol, 37, 281A Deswal, 1999, Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure, Circulation, 99, 3224, 10.1161/01.CIR.99.25.3224 Coletta, 2002, RENEWAL (RENAISSANCE and RECOVER) and ATTACH, Eur J Heart Fail, 4, 559, 10.1016/S1388-9842(02)00121-6 Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001 Zannad, 2000, Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure, Circulation, 102, 2700, 10.1161/01.CIR.102.22.2700 Stanley, 2001, Cardiac energetics during ischaemia and the rationale for metabolic interventions, Coron Artery Dis, 12, S3 Anderson, 2001, Ranolazine—a potential new treatment for chronic stable angina, Heart Dis, 3, 263, 10.1097/00132580-200107000-00009 Mehra, 2002, Emergence of Laplace therapeutics, Congest Heart Fail, 8, 228, 10.1111/j.1527-5299.2002.01417.x Garrido, 2002, New surgical treatments for heart failure, Curr Cardiol Rep, 4, 233, 10.1007/s11886-002-0056-y Saad, 2002, Current status and future expectations for multisite pacing in heart failure, Curr Cardiol Rep, 4, 238, 10.1007/s11886-002-0057-x Jahaveri, 1998, Sleep apnea in 81 ambulatory male patients with stable heart failure, Circulation, 97, 2154, 10.1161/01.CIR.97.21.2154 Bradley, 1996, Pathophysiology and therapeutic implications of sleep apnoea in congestive heart failure, J Card Fail, 2, 223, 10.1016/S1071-9164(96)80045-5 Sin, 2000, Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration, Circulation, 102, 61, 10.1161/01.CIR.102.1.61 Tkacova, 1997, Effects of continuous positive airway pressure on atrial natriuretic peptide and mitral regurgitant fraction in patients with heart failure and central sleep apnea, J Am Coll Cardiol, 30, 10.1016/S0735-1097(97)00199-X Silverberg, 2001, Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases, Perinat Dial Int, 21, S236, 10.1177/089686080102103S42 Maxwell, 2002, Influence of progressive renal dysfunction in chronic heart failure, Eur J Heart Fail, 4, 125, 10.1016/S1388-9842(01)00238-0 Udelson, 2001, 26 adenosine agonists, Circulation, 104, 2417, 10.1161/hc4501.099313 Gottlieb, 2002, BG9719 (CVT-124), an A1adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy, Circulation, 105, 1348, 10.1161/hc1102.105264 Senior, 2001, Effect of revascularization on left ventricular remodeling in patients with heart failure from severe chronic ischemic left ventricular dysfunction, Am J Cardiol, 88, 624, 10.1016/S0002-9149(01)01803-3 Graham, 2001, To anticoagulate or not to anticoagulate patients with cardiomyopathy, Cardiol Clin, 19, 605, 10.1016/S0733-8651(05)70247-2 Moss, 2002, Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction, N Engl J Med, 346, 877, 10.1056/NEJMoa013474